Compugen Announces USPTO Grants New Patent for Use of COM902

TipRanksNov 27 07:06 ET

Express News | Compugen Expands Its Intellectual Property Portfolio With New U.S. Patent Covering Triple Combination Use of Com902 (Reduced Fc Anti-Tigit) With Anti-Pd-1 and Anti-Pvrig Antibodies

ReutersNov 27 07:00 ET

Roche Anti-TIGIT Therapy Fails to Extend Survival in Late-stage Lung Cancer Trial

Seeking AlphaNov 26 06:53 ET

Compugen Ltd. (NASDAQ:CGEN) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?

Yahoo FinanceNov 15 05:11 ET

Truist Financial Maintains Compugen(CGEN.US) With Buy Rating

Moomoo NewsNov 13 07:31 ET · Ratings

Compugen Reports Strong Q3 2024 Results and Progress

TipRanksNov 12 23:22 ET